← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $169B	1,737	+131	+8%	$138B
2	2 Amgen AMGN $238B	1,155	+93	+9%	$70.1B
3	3 Eli Lilly LLY $1.13T	1,005	+31	+3%	$42.2B
4	4 Becton Dickinson BDX $52.5B	831	+27	+3%	$17.7B
5	5 McKesson MCK $116B	792	+89	+13%	$31.7B
6	6 Teva Pharmaceutical Industries Limited TEVA $48.1B	728	+23	+3%	$18.3B
7	7 Conagra Brands CAG $6.83B	620	+35	+6%	$9.58B
8	8 DaVita DVA $11.9B	456	+42	+10%	$11.4B
9	9 Regeneron Pharmaceuticals REGN $82.4B	438	+24	+6%	$21B
10	10 Novo Nordisk NVO $174B	432	+7	+2%	$6.39B
11	11 AstraZeneca AZN $260B	380	+37	+11%	$8.01B
12	12 ResMed RMD $33.9B	329	+7	+2%	$3.84B
13	13 Herbalife HLF $1.52B	328	+25	+8%	$7.62B
14	14 Accendra Health ACH $21.1M	243	+16	+7%	$2.28B
15	15 West Pharmaceutical WST $26.9B	230	+25	+12%	$3.1B
16	16 DELISTED WW International WW	179	-1	-0.6%	$2.07B
17	17 Opko Health OPK $1.17B	156	+1	+0.6%	$599M
18	18 Dr. Reddy's Laboratories RDY $10.8B	149	+8	+6%	$931M
19	19 MannKind Corp MNKD $1.02B	144	+11	+8%	$409M
20	20 Tootsie Roll Industries TR $2.9B	138	0	0%	$454M
21	21 Fresenius Medical Care FMS $11.8B	135	+5	+4%	$573M
22	ARNA 22 DELISTED Arena Pharmaceuticals Inc ARNA	134	-6	-4%	$630M
23	23 Medifast MED $135M	127	-13	-9%	$311M
24	24 Lexicon Pharmaceuticals LXRX $730M	109	+7	+7%	$846M
25	25 Destination XL Group DXLG $24.6M	91	+8	+10%	$257M